References
- Raskind MA, Peskind ER, Wessel T, Yuan W, and the Galantamine USA-1 Study Group. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54: 2261–8
- Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D, on behalf of the Galantamine International-2 Study Group. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71: 589–95
- Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C, and the Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54: 2269–76
- Wilcock GK, Lilienfeld S, Gaens E, on behalf of the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000;321: 1445–9
- Yamada H, Sugiyama T, Ashida T, Ohwaki H, Fujii J. Medication management skill and regimen compliance are deteriorated in the elderly even without obvious dementia. Yakugaku Zasshi 2001;121:187–90
- Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice- daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002;95: 68–71
- Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296–310
- Brodaty H, Yan B, Damaraju CV, Gold M. Safety and tolerability of once-daily galantamine prolonged-release capsule in patients with mild to moderate Alzheimer's disease. Poster presented at: 8th European Federation of Neurological Societies; September 4–7, 2004; Paris, France
- Piotrovsky V, Van Peer A, Van Osselaer N, Armstrong M, Aerssens J. Galantamine population pharmacokinetics in patients with Alzheimer’s disease: modeling and simulations. J Clin Pharmacol 2003;43:514–23
- Kewitz H. Pharmacokinetics and metabolism of galanthamine. Drugs Today 1997;33:265–72
- Mihailova D, Yamboliev I, Zhivkova Z, Tencheva J; Jovovich V. Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology 1989;39:50–8
- REMINYL [package insert]. Titusville, NJ. Janssen Pharmaceutica Products, LP; 2003